Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer.

Yano K, Kaseda K, Nakamura K, Okubo Y, Masai K, Hishida T, Nukaga S, Ohgino K, Terai H, Yasuda H, Kurebayashi Y, Fukunaga K, Nishihara H, Asakura K

Open source

DOI
10.1038/s41598-025-21559-5
Published
2025 Oct 27
Container
Scientific reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41598-025-21559-5,
  title = {Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer.},
  author = {Yano K and Kaseda K and Nakamura K and Okubo Y and Masai K and Hishida T and Nukaga S and Ohgino K and Terai H and Yasuda H and Kurebayashi Y and Fukunaga K and Nishihara H and Asakura K},
  year = {2025},
  journal = {Scientific reports},
  doi = {10.1038/s41598-025-21559-5},
  url = {https://doi.org/10.1038/s41598-025-21559-5}
}

RIS

TY  - JOUR
TI  - Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer.
AU  - Yano K
AU  - Kaseda K
AU  - Nakamura K
AU  - Okubo Y
AU  - Masai K
AU  - Hishida T
AU  - Nukaga S
AU  - Ohgino K
AU  - Terai H
AU  - Yasuda H
AU  - Kurebayashi Y
AU  - Fukunaga K
AU  - Nishihara H
AU  - Asakura K
PY  - 2025
JO  - Scientific reports
DO  - 10.1038/s41598-025-21559-5
UR  - https://doi.org/10.1038/s41598-025-21559-5
ER  - 

APA

K, Y., K, K., K, N., Y, O., K, M., T, H., S, N., K, O., H, T., H, Y., Y, K., K, F., H, N., & K, A. (2025). Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer.. Scientific reports. https://doi.org/10.1038/s41598-025-21559-5

Source records